Skip to main content
Journal cover image

Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer.

Publication ,  Journal Article
Vaidyanathan, G; Groman, A; Wilding, G; Fakih, MG
Published in: Oncology
2010

BACKGROUND: Infusional 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX) plus bevacizumab chemotherapy is commonly implemented in the first-line treatment of metastatic colorectal cancer. A stop and go oxaliplatin strategy has been recommended to reduce oxaliplatin-associated neuropathy. Despite the acceptance of this strategy by community and academic practices, efficacy data with this approach are limited. METHODS: We analyzed the efficacy of a stop and go FOLFOX regimen combined with bevacizumab in a single institute between January 2007 and December 2009. Oxaliplatin was withdrawn electively after 8 cycles of treatment and patients were maintained on 5-fluorouracil/leucovorin and bevacizumab until progression. When feasible, patients were rechallenged with oxaliplatin upon progression. RESULTS: Sixty-seven patients were treated and analyzed for outcome. The response rate of this group was 58%. The median progression-free and overall survival was 10.6 and 26.7 months, respectively. The median duration of disease control in the 18-patient subgroup that was rechallenged with oxaliplatin was 21.2 months. CONCLUSIONS: Elective withdrawal of oxaliplatin after 8 cycles in the setting of FOLFOX and bevacizumab does not appear to compromise the activity of this regimen. A stop and go approach of FOLFOX plus bevacizumab is effective and may reduce treatment costs and toxicity in comparison with a continuous FOLFOX treatment strategy.

Duke Scholars

Published In

Oncology

DOI

EISSN

1423-0232

Publication Date

2010

Volume

79

Issue

1-2

Start / End Page

67 / 71

Location

Switzerland

Related Subject Headings

  • Treatment Outcome
  • Retrospective Studies
  • Organoplatinum Compounds
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Leucovorin
  • Kaplan-Meier Estimate
  • Humans
  • Fluorouracil
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Vaidyanathan, G., Groman, A., Wilding, G., & Fakih, M. G. (2010). Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer. Oncology, 79(1–2), 67–71. https://doi.org/10.1159/000319549
Vaidyanathan, Gayatri, Adrienne Groman, Gregory Wilding, and Marwan G. Fakih. “Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer.Oncology 79, no. 1–2 (2010): 67–71. https://doi.org/10.1159/000319549.
Vaidyanathan G, Groman A, Wilding G, Fakih MG. Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer. Oncology. 2010;79(1–2):67–71.
Vaidyanathan, Gayatri, et al. “Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer.Oncology, vol. 79, no. 1–2, 2010, pp. 67–71. Pubmed, doi:10.1159/000319549.
Vaidyanathan G, Groman A, Wilding G, Fakih MG. Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer. Oncology. 2010;79(1–2):67–71.
Journal cover image

Published In

Oncology

DOI

EISSN

1423-0232

Publication Date

2010

Volume

79

Issue

1-2

Start / End Page

67 / 71

Location

Switzerland

Related Subject Headings

  • Treatment Outcome
  • Retrospective Studies
  • Organoplatinum Compounds
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Leucovorin
  • Kaplan-Meier Estimate
  • Humans
  • Fluorouracil